The DOI matches its Crossref record; 16 of the 16 references it cites were found in a registry or an index.
Nicotine as a potential neuroprotective agent for Parkinson's disease
Open accessAbstract
Converging research efforts suggest that nicotine and other drugs that act at nicotinic acetylcholine receptors (nAChRs) may be beneficial in the management of Parkinson's disease. This idea initially stemmed from the results of epidemiological studies that demonstrated that smoking is associated with a decreased incidence of Parkinson's disease. The subsequent finding that nicotine administration protected against nigrostriatal damage in parkinsonian animal models led to the idea that nicotine in tobacco products may contribute to this apparent protective action. Nicotine most likely exerts its effects by interacting at nAChRs. Accumulating research indicates that multiple subtypes containing nAChRs, including α4β2, α6β2, and/or α7, may be involved. Stimulation of nAChRs initially activates various intracellular transduction pathways primarily via alterations in calcium signaling. Consequent adaptations in immune responsiveness and trophic factors may ultimately mediate nicotine's ability to reduce/halt the neuronal damage that arises in Parkinson's disease. In addition to a potential neuroprotective action, nicotine also has antidepressant properties and improves attention/cognition. Altogether, these findings suggest that nicotine and nAChR drugs represent promising therapeutic agents for the management of Parkinson's disease. © 2012 Movement Disorder Society
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Staging of brain pathology related to sporadic Parkinson’s disease
Braak, H., Tredici, K. D., Rüb, U., de Vos, R. A. I., Jansen Steur, E. N. H., & Braak, E. (2003) · Neurobiology of Aging · doi:10.1016/s0197-4580(02)00065-9 · Cited by 10,777
Neuroinflammation in Parkinson’s disease: A target for neuroprotection?
Hirsch, E. C., & Hunot, S. (2009) · The Lancet Neurology · doi:10.1016/s1474-4422(09)70062-6 · Cited by 1,984
Mammalian nicotinic acetylcholine receptors: from structure to function
Albuquerque, E. X., Pereira, E. F. R., Alkondon, M., & Rogers, S. W. (2009) · Physiological Reviews · doi:10.1152/physrev.00015.2008 · Cited by 1,724
Benowitz, N. L. (2010) · New England Journal of Medicine · doi:10.1056/nejmra0809890 · Cited by 1,508
Pan-Montojo, F., Anichtchik, O., Dening, Y., Knels, L., Pursche, S., Jung, R., Jackson, S., Gille, G., Spillantini, M. G., Reichmann, H., et al. (2010) · PLoS ONE · doi:10.1371/journal.pone.0008762 · Cited by 524
Reward, addiction, withdrawal to nicotine
De Biasi, M., & Dani, J. A. (2011) · Annual Review of Neuroscience · doi:10.1146/annurev-neuro-061010-113734 · Cited by 366
Nonmotor symptoms as presenting complaints in Parkinson’s disease: a clinicopathological study
O'Sullivan, S. S., Williams, D. R., Gallagher, D. A., Massey, L. A., Silveira‐Moriyama, L., & Lees, A. J. (2008) · Movement Disorders · doi:10.1002/mds.21813 · Cited by 290 · cited 1×
“This would help retard declines in motor function and also in nonmotor deficits, including olfactory and autonomic problems, sleep disorders, cognitive declines, depression, and pain.(4,7,121,122) In addition to a neuroprotective role, nicotine treatment may directly improve some of these nonmotor complications, as an…”
BackgroundThe subtypes of nicotinic acetylcholine receptors on dopaminergic terminals of mouse striatum
Grady, S. R., Salminen, O., Laverty, D. C., Whiteaker, P., McIntosh, J. M., Collins, A. C., & Marks, M. J. (2007) · Biochemical Pharmacology · doi:10.1016/j.bcp.2007.07.032 · Cited by 252
Gotti, C., Guiducci, S., Tedesco, V., Corbioli, S., Zanetti, L., Moretti, M., Zanardi, A., Rimondini, R., Mugnaini, M., Clementi, F., et al. (2010) · The Journal of Neuroscience · doi:10.1523/jneurosci.5095-09.2010 · Cited by 226
Ryan, R. E., Ross, S. A., Drago, J., & Loiacono, R. E. (2001) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0703989 · Cited by 188
Cited by
Oxidative & nitrosative stress in depression: Why so much stress?
Moylan, S., Berk, M., Dean, O. M., Samuni, Y., Williams, L. J., O’Neil, A., Hayley, A. C., Pasco, J. A., Anderson, G., Jacka, F. N., et al. (2014) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2014.05.007 · Cited by 403
The ongoing pursuit of neuroprotective therapies in Parkinson disease
Athauda, D., & Foltynie, T. (2015) · Nature Reviews Neurology · doi:10.1038/nrneurol.2014.226 · Cited by 269
The habenulo-interpeduncular pathway in nicotine aversion and withdrawal
Antolin-Fontes, B., Ables, J. L., Görlich, A., & Ibañez-Tallon, I. (2015) · Neuropharmacology · doi:10.1016/j.neuropharm.2014.11.019 · Cited by 154
Linking Smoking, Coffee, Urate, and Parkinson’s Disease – A Role for Gut Microbiota?
Scheperjans, F., Pekkonen, E., Kaakkola, S., & Auvinen, P. (2015) · Journal of Parkinson’s Disease · doi:10.3233/jpd-150557 · Cited by 83
Moist smokeless tobacco (Snus) use and risk of Parkinson’s disease
Yang, F., Pedersen, N. L., Ye, W., Liu, Z., Norberg, M., Forsgren, L., Trolle Lagerros, Y., Bellocco, R., Alfredsson, L., Knutsson, A., et al. (2016) · International Journal of Epidemiology · doi:10.1093/ije/dyw294 · Cited by 34
Metadata
- Authors
- Quik, M., Perez, X. A., & Bordia, T.
- Venue
- Movement Disorders
- Publisher
- Wiley
- Published
- 2012-06-12
- Volume
- 27
- Issue
- 8
- Pages
- 947-957
- ISSN
- 0885-3185 (ISSN-L)
- 1531-8257
- OpenAlex
- W2030764484
- Cited by
- 242
- References
- 16
- FWCI
- 13.65
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Nicotine as a potential neuroprotective agent for Parkinson's disease. https://app.cochat.ai/papers/10.1002/mds.25028
- The paper
- Quik, M., Perez, X. A., & Bordia, T. (2012). Nicotine as a potential neuroprotective agent for Parkinson's disease. Movement Disorders. https://doi.org/10.1002/mds.25028
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.
